Pharmacokinetics of oral melatonin in high-risk critically ill : standard formulation vs incapsulation in solid lipid nanoparticles (SLN) by B. Salihovic et al.
 
PHARMACOKINETICS OF ORAL MELATONIN IN HIGH-RISK CRITICALLY ILL: 
STANDARD FORMULATION VS INCAPSULATION IN SOLID LIPID 
NANOPARTICLES (SLN). 
 
Salihovic B.*, Ferrari F.*, Mistraletti G.*, Mantovani E.*, Paroni R.°, Finati E.°, Fraschini F.§, 
Galluccio I.* , Cerri B.*, Marzorati S.*, Iapichino G.* 
 
* – Dipartimento di Anestesiologia, Università degli Studi di Milano 
° – Dipartimento di Medicina, Università degli Studi di Milano 
§ – Dipartimento di Farmacologia, Università degli Studi di Milano 
 
 
Introduction 
Melatonin could be useful in critically ill thanks to its antioxidant, immunomodulating, and 
hypnagogue effects. When administered orally, its bioavailability is limited by a marked first 
pass hepatic metabolism. Incorporation in SLN, targeted to lymph after enteral administration 
may create a sustained release delivery system. This could maintain a prolonged blood 
concentration, and allow cellular internalization independent from MT1/MT2 membrane 
receptors. 
 
Methods 
In high-risk critically ill (SAPS II>32, mechanical ventilation >48 hours), repeated blood 
sampling were performed to assess melatonin levels from 2nd ICU day at 8 pm (endogenous 
levels) to 4th ICU day. Melatonin 3 mg (standard or incorporated in SLN) was administered via 
naso-gastric (NGT) or naso-jejunal (NJT) tube on 3rd ICU day at 8 pm. 
 
Results 
12 patients were enrolled. Age 68±11 years. SAPS II 49±11. Lenght of ICU stay 13 [10-16] 
days. Diagnosis: acute lung injury (5), septic shock (2), necrotizing fasciitis, abruption of aortic 
aneurism, pleural empyema, acute myocardial infarction, diabetes insipidus. 3 patients had NJT, 
while 9 NGT. Metoclopramide was used in 4 patients. 
Both standard and SLN-melatonin formulations reached pharmacological blood levels 5 minutes 
after administration (p<0.01). A significant difference between groups rose from 30 minutes to 3 
hours with SLN levels up to four time higher than standard formulation (p<0.05). 
Pharmacological blood levels lasted up to 10 hours with both formulations, with a trend in 
favour of SLN-melatonin (p<0.08). 
 
Conclusions 
SLN-melatonin seems to have a more favourable pharmacokinetic profile in order to determine 
meaningful clinical effects. 
